clarithromycin vs vorapaxar
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of clarithromycin and vorapaxar. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Strong CYP3A Inhibitors Avoid concomitant use of ZONTIVITY with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] .
Biaxin
Zontivity
Clarithromycin is an antibiotic that fights bacterial infections. It belongs to a class of drugs called macrolides.
Vorapaxar (Zontivity) helps prevent blood clots if you have had a heart attack or have peripheral artery disease. It works by stopping platelets in your blood from sticking together and forming clots.
Clarithromycin treats mild to moderate infections caused by certain bacteria. It can treat bronchitis, sinus infections, pneumonia, and throat/tonsil infections. It also treats skin infections, ear infections in children, certain mycobacterial infections, and H. pylori infections that cause ulcers.
Vorapaxar is used to lower the chance of having serious heart problems if you have a history of heart attack or peripheral artery disease (PAD). PAD is when you have narrowed arteries that reduce blood flow to your limbs. This medicine can help prevent heart death, heart attack, stroke, and the need for urgent procedures to open blocked heart arteries.
Clarithromycin works by stopping the growth of bacteria. It prevents bacteria from making proteins they need to survive. This helps your body fight off the infection.
Vorapaxar is a PAR-1 antagonist, which means it blocks a specific receptor on platelets. This receptor, called protease-activated receptor-1 (PAR-1), normally causes platelets to clump together. By blocking PAR-1, vorapaxar helps prevent blood clots from forming.
- • Abdominal pain
- • Diarrhea
- • Nausea
- • Vomiting
- • Taste changes
- • Bleeding
- Drug Interaction 2,906
- Nausea 2,214
- Dyspnoea 1,959
- Diarrhoea 1,937
- Malaise 1,650
No adverse event reports.
Clarithromycin can cause severe allergic reactions. Stop taking it and get medical help right away if you have signs of a reaction. This medicine can also cause heart rhythm problems (QT prolongation) and liver problems. Tell your doctor if you have heart or liver issues. Clarithromycin may increase the risk of death in patients with coronary artery disease.
Vorapaxar can cause serious bleeding, including bleeding in the brain, which can be fatal. You should not take this medicine if you have a history of stroke, transient ischemic attack (TIA), or bleeding in the brain. Also, do not take it if you have active bleeding.
Clarithromycin is not recommended during pregnancy unless there are no other options. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if clarithromycin passes into breast milk, so talk to your doctor before breastfeeding.
It is not known if vorapaxar will harm an unborn baby. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Also Compare, Nearby Drugs
Compare clarithromycin with
How to Read This clarithromycin vs vorapaxar Comparison
clarithromycin is classified in the Macrolide Antibiotic drug class, while vorapaxar sits within the PAR-1 Antagonist (Antiplatelet) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, clarithromycin has 10,666 submissions while vorapaxar has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to clarithromycin stops your body from processing vorapaxar correctly, leading to higher amounts of the drug in your blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for clarithromycin or vorapaxar.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.